One of the great challenges for Medical Affairs is determining how to most effectively support a drug at launch. As you may know, drug launch is absolutely critical to the success of a drug. And since in our business that means the penetration of treatment to patients who needs them, MA must view launch as a unique opportunity to educate the healthcare community. In discussing this topic, I will address the following topics:
As usual, I am curious to hear about your experiences at launch. Please share them in the comments.
[...] There is often very little senior leadership to go around. Yet, as we mentioned in this post, it is critical to start MA up early to support a product launch that may be over two years away. [...]
ReplyDelete[...] have already discussed preparing an MA team for launch here, the effective way to manage MSL groups here and the best way to develop a MedInfo function here, [...]
ReplyDelete[...] discussed a range of topics including MSL proactivity, KOL identification, MedComm/SciComm groups, MA at Product Launch, Global MA and MA’s Relationship with Commercial, just to name a [...]
ReplyDelete[...] a range of topics including MSL proactivity, KOL identification, MedComm/SciComm groups, MA at Product Launch, Global MA and MA’s Relationship with Commercial, just to name a [...]
ReplyDelete[...] have posted about outsourcing in MA in past posts here and [...]
ReplyDelete